RE:RE:RE:RE:RE:Interesting Chart Pattern Shows.......While I appreciate these posts and the important points they convey, I remain very sceptical that the company has enough senior management with relevant experience to come even close to achieving what is called for in the recent notes. Look at the list from Oats of what is expected this fall. Who is managing all these projects? Who of any of those folks has any experience about clinical trials? About licencing? About marketing pharmaceuticals?
I have confidence in the Ceopro management to do the science and engineering to create the raw materials, and get the factories and equipment needed to make the raw products, but on every other front, they appear to need a whole lot more staff. They show no signs of recognizing their management capacity limitations.
If all this turns into another strange turn of events, like for example purchasing Juvente, I will be royally disappointed.